Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Colorcon
US Army
Boehringer Ingelheim
Chinese Patent Office
Queensland Health
Mallinckrodt
Daiichi Sankyo
Fuji

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,080,428

« Back to Dashboard

Which drugs does patent 6,080,428 protect, and when does it expire?


Patent 6,080,428 protects NIASPAN and NIASPAN TITRATION STARTER PACK and is included in one NDA.

This patent has twenty-four patent family members in ten countries.

Summary for Patent: 6,080,428

Title: Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
Abstract:An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally", that is in the evening or at night.
Inventor(s): Bova; David J. (Hollywood, FL)
Assignee:
Application Number:08/368,378
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997ABRXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997ABRXYesYes► Subscribe► Subscribe► SubscribeREDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997ABRXYesYes► Subscribe► Subscribe► SubscribeREDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997ABRXYesYes► Subscribe► Subscribe► SubscribeREDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-001Jul 28, 1997DISCNNoNo► Subscribe► Subscribe► SubscribeMETHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeMETHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeREDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
AbbvieNIASPANniacinTABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeREDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,080,428

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,998,506Nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night► Subscribe
7,011,848Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
6,746,691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics► Subscribe
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia► Subscribe
6,676,967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia► Subscribe
6,406,715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,080,428

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway994275► Subscribe
European Patent Office0643965► Subscribe
European Patent Office0966284► Subscribe
European Patent Office0969837► Subscribe
European Patent Office2319513► Subscribe
Spain2234100► Subscribe
Finland991895► Subscribe
Finland119910► Subscribe
Finland991896► Subscribe
Australia775967► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Citi
Harvard Business School
Chubb
Julphar
Healthtrust
Cantor Fitzgerald
UBS
Accenture
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot